Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IM-3050

Radiopharmaceutical · Kills target cells, directed at fibroblast activation protein (FAP) · developed by Immunome

Phase 1 Most advanced trial
IMNM Developer
1 Registered trials

What is IM-3050?

177Lu-IM-3050 is a radioconjugate of IM-3050, a small molecule ligand that binds fibroblast activation protein (FAP), a cell surface protein overexpressed on cancer-associated fibroblasts and certain tumor cells. Its albumin-binding domain extends circulation time, and the attached lutetium-177 beta emitter delivers cytotoxic radiation to FAP-expressing cells. It is being studied in solid malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Radiopharmaceutical
Targets
fibroblast activation protein (FAP)
Mechanism
Kills target cells, directed at fibroblast activation protein (FAP)
Therapy area
Oncology
Developer
Immunome, Inc. (IMNM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07505771 Phase 1 Solid Malignancies Recruiting IMNM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Malignancies

Other drugs acting on FAP

More from Immunome

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IMNM page.

Follow IMNM, the company behind IM-3050

See IMNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMNM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.